Prostate cancer cell growth and death: Complex roles of pro- and anti-oncogenic protein signaling

Handbook of Prostate Cancer Cell Research: Growth, Signalling, and Survival

Volumn , Issue , 2009, Pages 431-447

  Lu, Qun ^a   Zhang, Jiao ^a,b   Chen, Yan Hua ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950605981     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (107)

1. Jemal, A., et al., (2008). Cancer statistics, 2008. CA Cancer J Clin., 58(2), 71-96.
2. Sakr, W. A., et al. (2000). Epidemiology and molecular biology of early prostatic neoplasia. Mol Urol., 4(3), 109-13; discussion 115.
3. Barrack, E. R. (1997). TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate, 31(1), 61-70.
4. Jakowlew, S. B. (2006). Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev., 25(3), 435-57.
5. Bello-DeOcampo, D. & Tindall, D. J. (2003). TGF-betal/Smad signaling in prostate cancer. Curr Drug Targets., 4(3), 197-207.
6. Abate-Shen, C. & Shen, M. M. (2000). Molecular genetics of prostate cancer. Genes Dev, 14(19), 2410-34.
7. Isaacs, J. T. (1994). Advances and controversies in the study of programmed cell death/apoptosis in the development of and therapy for cancer. Curr Opin Oncol., 6(1), 82-9.
8. Berges, R. R. et al., (1995). Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res., 1(5), 473-80.
9. Weinberg, R. A. (2006). The Biology of Cancer. 2006 ed., London: Garland Science.
10. Iaquinta, P. J. & Lees, J. A. (2007). Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol., 19(6), 649-57.
11. Taghavi, P., et al. (2008). In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene.
12. Pierce, A. M., et al. (1999). E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol Cell Biol., 19(9), 6408-14.
13. Wang, D., Russell, J. L. & Johnson, D. G. (2000). E2F4 and E2F1 have similar proliferative properties but different apoptotic and oncogenic properties in vivo. Mol Cell Biol., 20(10), 3417-24.
14. Davis, J. N., et al. (2006). Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res., 66(24), 11897-906.
15. Kaseb, A. O., et al. (2007). Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res., 67(16), 7782-8.
16. Fisher, G. H., et al. (2001). Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev, 15(24), 3249-62.
17. Macias-Perez, I., et al. (2008). Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer. Cancer Res., 68(15), 6127-35.
18. Zhang, Z., et al. (2001). Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet., 29(1), 25-33.
19. Cho, N. Y., et al. (2006). BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer, 119(8), 1858-62.
20. Zhou, H., et al. (1998). Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet, 20(2), 189-93.
21. Lu, L. Y., et al. (2008). Aurora a is essential for early embryonic development and tumor suppression. J Biol Chem., 283(46), 31785-90.
22. Peifer, M., Berg, S. & Reynolds, A. B. (1994). A repeating amino acid motif shared by proteins with diverse cellular roles. Cell, 76(5), 789-91.
23. Polakis, P. (2000). Wnt signaling and cancer. Genes Dev, 14(15), 1837-51.
24. Voeller, H. J., Truica, C. I. & Gelmann, E. P. (1998). Beta-catenin mutations in human prostate cancer. Cancer Res., 58(12), 2520-3.
25. Chesire, D. R., et al. (2000). Detection and analysis of beta-catenin mutations in prostate cancer. Prostate, 45(4), 323-34.
26. Kim, K., et al. (2000). Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. Mol Biol Cell, 11(10), 3509-23.
27. Kotliarova, S., et al. (2008). Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res., 68(16), 6643-51.
28. Terry, S., et al. (2006). Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem., 99(2), 402-10.
29. Yang, X., et al. (2006). Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene, 25(24), 3436-44.
30. Yu, X., et al. (2008). Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate.
31. Kinzler, K. W. & Vogelstein, B. (1996). Lessons from hereditary colorectal cancer. Cell, 87(2), 159-70.
32. Hanson, C. A. & Miller, J. R. (2005). Non-traditional roles for the Adenomatous Polyposis Coli (APC) tumor suppressor protein. Gene, 361, 1-12.
33. Dobosy, J. R., et al. (2007). The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol., 177(3), 822-31.
34. Kawasaki, Y., Sato, R. & Akiyama, T. (2003). Mutated APC and Asef are involved in the migration of colorectal tumour cells. Nat Cell Biol., 5(3), 211-5.
35. Tighe, A., Johnson, V. L. & Taylor, S. S. (2004). Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability. J Cell Sci., 117(Pt 26), 6339-53.
36. Caldwell, C. M., Green, R. A. & Kaplan, K. B. (2007). APC mutations lead to cytokinetic failures in vitro and tetraploid genotypes in Min mice. J Cell Biol., 178(7), 1109-20.
37. Kallakury, B. V., et al. (2001). Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer, 92(11), 2786-95.
38. Kallakury, B. V., Sheehan, C. E. & Ross, J. S. (2001). Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol., 32(8), 849-55.
39. Lu, Q., et al. (2005). Increased expression of delta-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer. Hum Pathol., 36(10), 1037-48.
40. Ireton, R. C., et al. (2002). A novel role for p120 catenin in E-cadherin function. J Cell Biol., 159(3), 465-76.
41. Nagafuchi, A., Takeichi, M. & Tsukita, S. (1991). The 102 kd cadherin-associated protein: similarity to vinculin and posttranscriptional regulation of expression. Cell, 65(5), 849-57.
42. Papkoff, J. (1997). Regulation of complexed and free catenin pools by distinct mechanisms. Differential effects of Wnt-1 and v-Src. J Biol Chem., 272(7), 4536-43.
43. van Oort, I. M., et al. (2007). The prognostic value of E-cadherin and the cadherinassociated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. Prostate, 67(13), 1432-8.
44. Anastasiadis, P. Z., et al. (2000). Inhibition of RhoA by p120 catenin. Nat Cell Biol., 2(9), 637-44.
45. Thoreson, M. A. & Reynolds, A. B. (2002). Altered expression of the catenin p120 in human cancer: implications for tumor progression. Differentiation, 70(9-10), 583-9.
46. Anastasiadis, P. Z. & Reynolds, A. B. (2001). Regulation of Rho GTPases by p120- catenin. Curr Opin Cell Biol., 13(5), 604-10.
47. Grosheva, I., et al. (2001). p120 catenin affects cell motility via modulation of activity of Rho-family GTPases: a link between cell-cell contact formation and regulation of cell locomotion. J Cell Sci., 114(Pt 4), 695-707.
48. Noren, N. K., et al. (2000). p120 catenin regulates the actin cytoskeleton via Rho family GTPases. J Cell Biol., 150(3), 567-80.
49. Reynolds, A. B., et al. (1996). The gene encoding p120cas, a novel catenin, localizes on human chromosome 11q11 (CTNND) and mouse chromosome 2 (Catns). Genomics, 31(1), 127-9.
50. Thoreson, M. A., et al. (2000). Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion. J Cell Biol., 148(1), 189-202.
51. Paffenholz, R. & Franke, W. W. (1997). Identification and localization of a neurally expressed member of the plakoglobin/armadillo multigene family. Differentiation, 61(5), 293-304.
52. Zhou, J., et al. (1997). Presenilin 1 interaction in the brain with a novel member of the Armadillo family. Neuroreport, 8(6), 1489-94.
53. Lu, Q., et al. (1999). delta-catenin, an adhesive junction-associated protein which promotes cell scattering. J Cell Biol., 144(3), 519-32.
54. Ho, C., et al. (2000). delta-catenin is a nervous system-specific adherens junction protein which undergoes dynamic relocalization during development. J Comp Neurol., 420(2), 261-76.
55. Burger, M. J., et al. (2002). Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int J Cancer, 100(2), 228-37.
56. Kim, K., et al. (2008). Identification of E2F1 as a positive transcriptional regulator for delta-catenin. Biochem Biophys Res Commun., 369(2), 414-20.
57. Westbrook, T. F., et al. (2005). A genetic screen for candidate tumor suppressors identifies REST. Cell, 121(6), 837-48.
58. Yu, C., et al. (2002). Pharmacologic mitogen-activated protein/extracellular signalregulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res., 62(1), 188-99.
59. Allen, L. F., Sebolt-Leopold, J. & Meyer, M. B. (2003). CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol., 30(5 Suppl 16), 105-16.
60. Milella, M., et al. (2001). Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest., 108(6), 851-9.
61. Milella, M., et al. (2002). Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood, 99(9), 3461-4.
62. Greene, L. A. & Tischler, A. S. (1976). Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A, 73(7), 2424-8.
63. Huff, K., End, D. & Guroff, G. (1981). Nerve growth factor-induced alteration in the response of PC12 pheochromocytoma cells to epidermal growth factor. J Cell Biol., 88(1), 189-98.
64. Marshall, C. J. (1995). Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 80(2), 179-85.
65. Bodo, J., et al. (2007). Isothiocyanate E-4IB induces MAPK activation, delayed cell cycle transition and apoptosis. Cell Prolif., 40(3), 316-26.
66. McCubrey, J. A., et al. (2006). Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul., 46, 249-79.
67. Hoyle, P. E., et al. (2000). Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia, 14(4), 642-56.
68. Chang, F. & McCubrey, J. A. (2001). P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene, 20(32), 4354-64.
69. Chang, F., Steelman, L. S. & McCubrey, J. A. (2002). Raf-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle, 1(3), 220-6.
70. Sanders, M. R., et al. (1998). The Raf-1 protein mediates insulin-like growth factorinduced proliferation of erythroid progenitor cells. Stem Cells, 16(3), 200-7.
71. Cioffi, C. L., et al. (1997). Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation. Mol Pharmacol., 51(3), 383-9.
72. Yen, A., et al. (1994). Expression of activated RAF accelerates cell differentiation and RB protein down-regulation but not hypophosphorylation. Eur J Cell Biol., 65(1), 103-13.
73. Ravi, R. K., et al. (1998). Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest., 101(1), 153-9.
74. Lloyd, A. C., et al. (1997). Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev, 11(5), 663-77.
75. Woods, D., et al. (1997). Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol., 17(9), 5598-611.
76. Shelton, J. G., et al. (2004). B-raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. Cell Cycle, 3(2), 189-96.
77. Shelton, J. G., et al. (2004). Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle, 3(3), 372-9.
78. Chanan-Khan, A. & Porter, C. W. (2006). Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol., 7(6), 480-8.
79. Basso, A. D., et al. (2002). Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene, 21(8), 1159-66.
80. Neshat, M. S., et al. (2001). Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A, 98(18), 10314-9.
81. Podsypanina, K., et al. (2001). An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A, 98(18), 10320-5.
82. Lee, J. T., Jr., Steelman, L. S. & McCubrey, J. A. (2005). Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. Int J Oncol., 26(6), 1637-44.
83. Lee, J. T., Jr. & McCubrey, J. A. (2002). The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia, 16(4), 486-507.
84. Shi, X. B., Tepper, C. G. & White, R. W. (2008). microRNAs and prostate cancer. J Cell Mol Med., 12(5A), 1456-65.
85. Calin, G. A. & Croce, C. M. (2006). MicroRNA signatures in human cancers. Nat Rev Cancer, 6(11), 857-66.
86. Wu, W., et al. (2007). MicroRNA and cancer: Current status and prospective. Int J Cancer, 120(5), 953-60.
87. Si, M. L., et al. (2007). miR-21-mediated tumor growth. Oncogene, 26(19), 2799-803.
88. Voorhoeve, P. M., et al. (2006). A genetic screen implicates miRNA-372 and miRNA- 373 as oncogenes in testicular germ cell tumors. Cell, 124(6), 1169-81.
89. Chang, T. C., et al. (2008). Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet, 40(1), 43-50.
90. Sylvestre, Y., et al. (2007). An E2F/miR-20a autoregulatory feedback loop. J Biol Chem., 282(4), 2135-43.
91. Galardi, S., et al. (2007). miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem., 282(32), 23716-24.
92. Musiyenko, A., Bitko, V. & Barik, S. (2008). Ectopic expression of miR-126.z.ast;, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med., 86(3), 313-22.
93. Lin, S.L., et al. (2008). Loss of mir-146a function in hormone-refractory prostate cancer. RNA, 14(3), 417-24.
94. Yoon, S. & De Micheli, G. (2005). Prediction of regulatory modules comprising microRNAs and target genes. Bioinformatics, 21 Suppl 2, ii93-100.
95. Bonci, D., et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med., 14(11), 1271-7.
96. Prueitt, R. L., et al. (2008). Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate, 68(11), 1152-64.
97. O'Donnell, K. A., et al. (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 435(7043), 839-43.
98. Murakami, Y., et al. (2006). Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene, 25(17), 2537-45.
99. Ciafre, S. A., et al. (2005). Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun., 334(4), 1351-8.
100. Chan, J. A., Krichevsky, A. M. & Kosik, K. S. (2005). MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res., 65(14), 6029-33.
101. Iorio, M. V., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res., 65(16), 7065-70.
102. Weinberg, B. D., et al. (2007). Antitumor efficacy and local distribution of doxorubicin via intratumoral delivery from polymer millirods. J Biomed Mater Res A., 81(1), 161-70.
103. Liu, J. Y., et al. (2008). The N-terminal domain of EBNA1 acts as a suppressor of the HER2/neu oncogene. Cancer Lett.
104. Criswell, T. L., et al. (2008). Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res., 68(18), 7304-12.
105. Yang, J., et al. (2008). Rb/E2F4 and Smad2/3 link survivin to TGF-beta-induced apoptosis and tumor progression. Oncogene, 27(40), 5326-38.
106. Acquaviva, J., Chen, X. & Ren, R. (2008). IRF-4 functions as a tumor suppressor in early B-cell development. Blood.
107. Wang, Z., et al. (2008). Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature, 455(7217), 1205-9.